• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Clinical evaluation of natalizumab for formulary consideration.
【24h】

Clinical evaluation of natalizumab for formulary consideration.

机译：那他珠单抗的临床评价用于处方考虑。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IMPORTANCE OF THE FIELD: Natalizumab is a monotherapy for relapsing forms of multiple sclerosis (MS) and maintaining remission in Crohn's disease (CD). Evaluation of natalizumab's clinical relevance must be performed before considering its place in treatment of these diseases. AREAS COVERED IN THIS REVIEW: MEDLINE and PubMed searches were performed using the keywords multiple sclerosis, Crohn's disease, natalizumab and clinical trials. The manufacturer's product information was consulted to extract additional data. Pivotal clinical trials included: Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM), Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing Remitting Multiple Sclerosis (SENTINEL), Efficacy of Natalizumab as Active Crohn's Therapy (ENACT)-1 and 2 and Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE). WHAT THE READER WILL GAIN: AFFIRM and SENTINEL showed improvements in progression of MS. ENACT-1 failed to show a significant effect, but the follow-up trials ENACT-2 and ENCORE were able to demonstrate a response to natalizumab. TAKE HOME MESSAGE: Two trials on efficacy of Tysabri for treatment of MS demonstrated positive results. Efficacy for CD was mixed. More research demonstrating head-to-head evidence against other agents is necessary to determine if Tysabri's benefits are significant.
机译：领域的重要性：纳他珠单抗是一种用于复发型多发性硬化症（MS）并维持克罗恩病（CD）缓解的单一疗法。必须先评估那他珠单抗的临床相关性，然后再考虑其在这些疾病的治疗中的地位。该评价涵盖的区域：MEDLINE和PubMed搜索使用关键词多发性硬化症，克罗恩病，那他珠单抗和临床试验进行。已咨询制造商的产品信息以提取其他数据。关键的临床试验包括：纳他珠单抗在复发性多发性硬化症中的安全性和有效性（AFFIRM），纳他珠单抗与干扰素Beta-1a联合治疗在复发性多发性硬化症中的安全性和有效性（SENTINEL），那他珠单抗作为有效的CrohnACT治疗（ -1和2以及那他珠单抗在克罗恩病反应和缓解中的作用（ENCORE）。读者的收获：AFFIRM和SENTINEL显示了MS进展的改善。 ENACT-1未能显示出明显的作用，但后续试验ENACT-2和ENCORE能够证明对那他珠单抗有反应。进行家庭消息：两项有关Tysabri治疗MS疗效的试验证明了积极的结果。 CD的疗效参差不齐。为了确定Tysabri的利益是否显着，需要开展更多的研究来与其他药物进行正面对比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号